• AZ Symbicort reduces rate of asthma attacks pharmatimes
    May 20, 2019
    AstraZeneca’s Novel START trial for its Symbicort Turbuhaler (budesonide/formoterol) demonstrated a reduction in the rate of asthma attacks in patients with mild asthma, compared to common therapies.
PharmaSources Customer Service